You are here

Lundbeck

The Top New York Biopharma Companies Hiring Now

BioSpace

Mon, 01/9/23 - 10:58 pm

FDA accepts Otsuka, Lundbeck filing for long-acting schizophrenia drug, teeing up April decision date

Fierce Pharma

Tue, 09/13/22 - 10:50 am

bipolar disorder

Abilify Maintena

Setback at Lundbeck: CGRP migraine drug Vyepti hits expansion snag, but sales still doubled

Fierce Pharma

Thu, 08/18/22 - 12:32 pm

Tracking mental health: Lundbeck partnership debuts US mapping dashboard tool

Endpoints

Sun, 02/20/22 - 11:51 am

Amid crowded migraine market, Lundbeck goes its own way

Pharmaforum

Mon, 11/15/21 - 10:42 am

Citing migraine drug growth and pandemic, Lundbeck to cut 300 jobs and close India facility

Endpoints

Fri, 11/12/21 - 10:39 am

Lundbeck taps Inscopix’ brain-mapping camera tech for CNS research

Pharmaforum

Mon, 09/20/21 - 10:59 pm

Lundbeck sells off flopped Alzheimer's drug as Aduhelm approval ups interest

Fierce Biotech

Fri, 07/2/21 - 11:05 am

Denovo Biopharma

Alzheimer's disease

2021 Best Places to Work in Medical Sales

MedReps.com

Tue, 12/22/20 - 10:58 am

Avion Pharmaceuticals

Spark Therapeutics

Lundbeck tops Q3 expectations following strong sales of mental health drugs

Pharmaforum

Tue, 11/3/20 - 10:47 am

Lundbeck gets cold feet, axes schizophrenia drug trial

Pharmaforum

Thu, 08/6/20 - 11:03 pm

clinical trials

Lilly touts Emgality's ability to reduce migraine patients' overall pain in first look at 'holistic approach'

Fierce Pharma

Wed, 06/17/20 - 09:52 pm

Teva Pharmaceutical

Lundbeck plotting up to 160 R&D job cuts as it rebuilds pipeline

Fierce Biotech

Tue, 06/9/20 - 12:22 pm

Ovid's lead drug shows promising efficacy signal in Fragile X syndrome study, but optimal dosing regimen is unclear for path forward

Endpoints

Fri, 05/8/20 - 10:34 am

Ovid Therapeutics

Fragile X syndrome

clinical trials

Lundbeck adds a Parkinson's flop to its list of setbacks, writing off a $1.1 billion deal on mid-stage failure

Endpoints

Mon, 03/30/20 - 10:47 am

Parkinson's Disease

The fourth CGRP migraine drug is here. Time for Lundbeck to prove it's worth $2B

Endpoints

Sat, 02/22/20 - 11:29 pm

Go or no go? Esperion's double whammy and a look to priority reviews

EP Vantage

Thu, 01/30/20 - 10:43 am

Esperion Therapeutics

Blueprint Medicines

Agile Therapeutics

Durect Corporation

Lundbeck’s digital strategy and how they manage global and local content

Pharmaforum

Tue, 10/15/19 - 10:20 am

digital strategy

digital marketing

Biopharma M&A: deal-depressed third quarter leaves nowhere to hide

EP Vantage

Tue, 10/8/19 - 10:53 am

Alder Biopharmaceuticals

Gilead Sciences

Vertex Pharmaceuticals

Swedish Orphan Biovitrum

Dova Pharmaceuticals

Alder's migraine drug attracted plenty of dealmakers. The company, not so much

Biopharma Dive

Wed, 09/25/19 - 09:17 am

Alder Biopharmaceuticals

Pages